<DOC>
	<DOCNO>NCT02247726</DOCNO>
	<brief_summary>The purpose study evaluate safety immunogenicity RSV-F protein nanoparticle vaccine , aluminum , healthy third-trimester pregnant woman assess impact maternal immunization infant safety one year life .</brief_summary>
	<brief_title>RSV F Vaccine Maternal Immunization Study Healthy Third-trimester Pregnant Women .</brief_title>
	<detailed_description />
	<mesh_term>Virus Diseases</mesh_term>
	<mesh_term>Respiratory Syncytial Virus Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Pregnant woman must meet follow criterion eligible participate : 1 . ≥18 ≤40 yearsofage . 2 . Singleton pregnancy 33 35 week gestation day plan vaccination . 3 . Good general maternal health demonstrate : Medical history ( include history adverse reaction prior vaccine allergy ) . Physical examination include least vital sign ( blood pressure , pulse , respiration , oral temperature ) ; weight ; height ; examination HEENT , cardiovascular , pulmonary , gastrointestinal ( abdominal ) , musculoskeletal , lymphatic , dermatologic organ system ; documentation fetal heart tone . Clinical laboratory parameter include normal blood urea nitrogen , creatinine , ALT , AST , total bilirubin , alkaline phosphatase ( ALP ) , hemoglobin , white blood count , platelet count ; serologic exclusion infection hepatitis B ( HBV ) C ( HCV ) viruses HIV ( require ) . Note normal range vital sign clinical laboratory parameter base third trimester value publish Sheffield et al . [ 2013 ] and/or reference range third trim pregnancy central laboratory . 4 . Documentation fulfill one following : Detailed ( level II ) second trimester later anatomic ultrasound significant anatomic growth abnormality identify ; OR Routine second trimester later ultrasound significant anatomic growth abnormality identify , PLUS least one follow : Normal first trimester screening ( base ultrasound + serum analytes ) ; Normal cellfree fetal DNA ; Normal chorionic villus sampling ( CVS ) amniocentesis ; Normal second trimester maternal serum quadruple screen ; Normal first second trimester screen use integrate , sequential , contingency approach ; Abnormal first second trimester screen follow normal CVS , amniocentesis , cellfree fetal DNA . 5 . Able understand , willing physically able comply study procedure . This include anticipation reasonable geographic proximity study clinic adequate transportation comply schedule unscheduled study followup visit . 6 . Able willing provide write informed consent infant . Pregnant woman exclude historical , physical examination , laboratory evidence follow criterion : 1 . Symptomatic cardiac pulmonary disease require chronic drug therapy , include hypertension asthma . Asthma exclusionary subject receive chronic systemic glucocorticoid dose inhaled glucocorticoid dose &gt; 500µg per day beclamethasone fluticasone , &gt; 800μg per day budesonide . 2 . Prepregnancy body mass index ( BMI ) ≥35 &lt; 18.5 . 3 . Hemoglobinopathy ( include know sickle trait thalassemia , even asymptomatic ) blood dyscrasia . 4 . Hepatic renal dysfunction . 5 . Established diagnosis seizure disorder , regardless therapy . 6 . Autoimmune disease know immunodeficiency syndrome . 7 . Endocrine disorder , include ( limited ) hyperthyroidism , untreated hypothyroidism , glucose intolerance ( e.g. , diabetes mellitus type 1 2 ) antedate pregnancy , occur pregnancy require intervention diet control . 8 . History major gynecologic major abdominal surgery , include bariatric surgery . 9 . Known HIV , HBV , HCV infection , assess serologic test conduct current pregnancy procedure screen period study . 10 . Primary genital herpes simplex ( HSV ) infection current pregnancy . 11 . Current alcohol drug abuse . 12 . Documentation current pregnancy result fertility treatment , rape , incest . 13 . Documentation infant ward state release adoption . 14 . Neuropsychiatric illness deem likely interfere protocol compliance , safety reporting , receipt prenatal care ; require treatment psychotropic drug . 15 . History/presence deep venous thrombosis thromboembolism , use anticoagulant pregnancy . 16 . Untreated red blood cell alloimmunization . 17 . Prior stillbirth neonatal death , multiple ( ≥3 ) spontaneous abortion . 18 . Prior preterm delivery ≤34 week gestation ongoing intervention ( medical/surgical ) current pregnancy prevent preterm birth . 19 . Greater five ( 5 ) prior delivery . 20 . Previous infant know genetic disorder major congenital anomaly . 21 . Receipt investigational drug immune globulin ( exception prophylactic antiRho D immune globulin ) within six ( 6 ) month prior administration study vaccine . 22 . Chronic administration ( define 14 continuous day ) immunosuppressant immunemodifying drug within 6 month prior administration study vaccine . An immunosuppressant dose glucocorticoid define systemic dose ≥10mg prednisone per day equivalent . The use topical , inhaled , nasal glucocorticoid permit except limit establish exclusion criterion # 1 . 23 . Any physical , psychiatric social condition may , investigator 's opinion , increase risk study participation maternal subject fetus/infant ; may lead collection incomplete inaccurate safety data .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>RSV</keyword>
	<keyword>Third Trimester</keyword>
	<keyword>Maternal Immunization</keyword>
</DOC>